RVY120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This first-in-human study will evaluate RVU120 (SEL120), a novel small molecule CDK8/19
inhibitor, in patients with Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic
Syndrome (HR-MDS), in terms of selection of the recommended dose for further clinical
development and assessment of safety, tolerability, preliminary anti-leukemic activity, as
well as pharmacokinetic and pharmacodynamic profiles.